Prenatal Care — MCQs

Prenatal Care Indian Medical PG Practice Questions and MCQs

Question 151: What is the recommended treatment for Chlamydia infection during pregnancy?

A. Doxycycline
B. Tetracycline
C. Azithromycin (Correct Answer)
D. Penicillin

Explanation: **Explanation:** The primary goal of treating Chlamydia trachomatis during pregnancy is to prevent maternal complications (pelvic inflammatory disease, preterm labor) and neonatal transmission (ophthalmia neonatorum, pneumonia). **Why Azithromycin is correct:** **Azithromycin (1g orally in a single dose)** is the first-line treatment recommended by the WHO and CDC for chlamydial infection in pregnancy. It is highly effective, has a high safety profile (Category B), and the single-dose regimen ensures 100% compliance, which is crucial in prenatal care. Amoxicillin is considered an alternative if Azithromycin is contraindicated. **Why other options are incorrect:** * **Doxycycline and Tetracycline:** These are the first-line treatments in non-pregnant adults. However, they are **contraindicated in pregnancy** (Category D) because they cross the placenta and can cause permanent yellow-brown discoloration of the deciduous teeth and inhibit fetal bone growth. * **Penicillin:** While safe in pregnancy, Penicillin is ineffective against *Chlamydia trachomatis* because Chlamydia is an obligate intracellular bacterium that lacks a typical peptidoglycan cell wall, making it resistant to beta-lactam antibiotics. **Clinical Pearls for NEET-PG:** * **Screening:** All pregnant women should be screened for Chlamydia at the first prenatal visit. * **Test of Cure (TOC):** Unlike in non-pregnant patients, a TOC (via Nucleic Acid Amplification Test - NAAT) is mandatory **3–4 weeks after treatment** in pregnancy to ensure eradication. * **Partner Treatment:** To prevent reinfection, the partner must be treated simultaneously (Expedited Partner Therapy). * **Neonatal Impact:** Chlamydial conjunctivitis typically appears 5–14 days after birth (later than Gonococcal conjunctivitis, which appears in 2–5 days).

Question 152: Raised beta-hCG levels are seen in which of the following conditions?

A. Diabetes Mellitus
B. Preeclampsia
C. Ectopic pregnancy (Correct Answer)
D. Rh incompatibility

Explanation: **Explanation:** The correct answer is **C. Ectopic pregnancy**. **Understanding the Concept:** Human Chorionic Gonadotropin (hCG) is produced by the syncytiotrophoblast cells of the placenta. In a normal intrauterine pregnancy, hCG levels typically double every 48–72 hours. While hCG levels in an ectopic pregnancy are generally **lower** than those of a viable intrauterine pregnancy of the same gestational age, they are still **raised** compared to the non-pregnant state. The detection of raised beta-hCG in the absence of an intrauterine gestational sac on ultrasound is the hallmark for diagnosing ectopic pregnancy. **Analysis of Incorrect Options:** * **A. Diabetes Mellitus:** Maternal diabetes is generally associated with normal or slightly altered placental function; it does not typically cause a pathognomonic rise in beta-hCG. * **B. Preeclampsia:** While some studies suggest a correlation between very high second-trimester hCG and the subsequent development of preeclampsia, it is not a primary diagnostic marker or a consistent finding compared to ectopic pregnancy. * **D. Rh Incompatibility:** Severe Rh isoimmunization (erythroblastosis fetalis) can lead to placental hypertrophy (placentomegaly), which may result in elevated hCG levels. However, in the context of standard NEET-PG questions, this is a secondary association rather than a primary diagnostic feature. **High-Yield Clinical Pearls for NEET-PG:** * **Discriminatory Zone:** The beta-hCG level at which an intrauterine sac should be visible on TVS is **1500–2000 mIU/mL**. If hCG is above this and the uterus is empty, suspect ectopic pregnancy. * **Doubling Time:** A rise of less than 66% in 48 hours is highly suggestive of an ectopic or non-viable pregnancy. * **Other conditions with very high hCG:** Molar pregnancy (highest levels), Multiple gestations, and Down Syndrome (Triple/Quadruple screen). * **Low hCG levels:** Seen in threatened or spontaneous abortion and ectopic pregnancy (relative to gestational age).

Question 153: The triple test for Down syndrome screening includes which of the following biochemical markers?

A. Maternal Alpha-fetoprotein (AFP), Human Chorionic Gonadotropin (HCG), and Estriol (Correct Answer)
B. Maternal Alpha-fetoprotein (AFP), Pregnancy-Associated Plasma Protein-A (PAPPA), and Human Chorionic Gonadotropin (HCG)
C. Maternal Alpha-fetoprotein (AFP), Pregnancy-Associated Plasma Protein-A (PAPPA), and Estriol
D. Thyroid-Stimulating Hormone (TSH), Human Chorionic Gonadotropin (HCG), and Estriol

Explanation: The **Triple Test** is a second-trimester screening tool (ideally performed between **15–20 weeks** of gestation) used to assess the risk of chromosomal abnormalities, primarily Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and neural tube defects (NTDs). ### 1. Why Option A is Correct The triple test measures three specific markers in the maternal serum: * **Alpha-fetoprotein (AFP):** Produced by the fetal yolk sac and liver. * **Human Chorionic Gonadotropin (HCG):** Produced by the placenta. * **Unconjugated Estriol (uE3):** Produced by the syncytiotrophoblast using precursors from the fetal adrenal glands and liver. In **Down syndrome**, the classic pattern is **"HI"** (High HCG and Inhibin-A), while **AFP and uE3 are decreased**. ### 2. Analysis of Incorrect Options * **Options B & C:** These include **PAPP-A** (Pregnancy-Associated Plasma Protein-A). PAPP-A is a **first-trimester marker** (measured between 11–13.6 weeks) and is not part of the second-trimester triple or quadruple screens. * **Option D:** **TSH** is a marker for thyroid function. While maternal thyroid health is vital, it is not a biochemical marker for screening fetal aneuploidy. ### 3. High-Yield Clinical Pearls for NEET-PG * **Quadruple Test:** Adds **Inhibin-A** to the triple test. In Down syndrome, Inhibin-A is **increased**. * **Neural Tube Defects (NTDs):** AFP is **elevated** (except in Down syndrome, where it is low). * **Edwards Syndrome (Trisomy 18):** All three markers (AFP, HCG, uE3) are **decreased**. * **Combined Test (1st Trimester):** Includes Nuchal Translucency (NT) scan + PAPP-A + beta-HCG. This is currently the preferred screening method due to higher sensitivity and earlier detection.

Question 154: All the following are advised in an epileptic woman preconceptionally except?

A. Attempt to achieve seizure control with monotherapy.
B. Supplement folic acid with a dose of 1mg/day. (Correct Answer)
C. Medication withdrawal is considered if a woman is seizure-free for 2 years or more.
D. Risk of congenital abnormalities in the fetus is dependent on the type, number, and dose of antiepileptic drugs.

Explanation: **Explanation:** The management of epilepsy in pregnancy focuses on balancing seizure control with minimizing teratogenic risks. **Why Option B is the correct answer (The "Except"):** Women taking Anti-Epileptic Drugs (AEDs) are at a significantly higher risk of having a child with Neural Tube Defects (NTDs) because many AEDs (especially Valproate and Carbamazepine) interfere with folate metabolism. To counteract this, the recommended preconception dose of **Folic Acid is 4–5 mg/day**, starting at least one month before conception and continuing through the first trimester. The standard dose of 0.4 mg or 1 mg is insufficient for this high-risk group. **Analysis of Incorrect Options:** * **Option A:** Monotherapy is the gold standard. Polytherapy significantly increases the risk of congenital malformations compared to a single agent. * **Option C:** If a patient has been seizure-free for **>2 years**, a supervised trial of tapering and withdrawing medication may be attempted before pregnancy to eliminate fetal drug exposure. * **Option D:** Teratogenicity is dose-dependent and drug-specific. For example, Valproate carries the highest risk (up to 10%), while Levetiracetam and Lamotrigine are considered safer alternatives. **NEET-PG High-Yield Pearls:** * **Drug of Choice:** Lamotrigine or Levetiracetam are preferred in pregnancy. * **Avoid:** Valproate (highest risk of NTDs and cognitive impairment). * **Vitamin K:** If the mother is on enzyme-inducing AEDs (e.g., Phenytoin, Phenobarbital), 10 mg of Vitamin K is given to the mother in the last month of pregnancy, and 1 mg is given to the neonate at birth to prevent Hemorrhagic Disease of the Newborn. * **Breastfeeding:** Generally encouraged as the benefits outweigh the risks of drug excretion in milk.

Question 155: Which nutrient requirement cannot be compensated by dietary intake during pregnancy?

A. Iron (Correct Answer)
B. Protein
C. Carbohydrate
D. Fats

Explanation: **Explanation:** The correct answer is **Iron (A)**. During pregnancy, the total iron requirement is approximately **1000 mg** (300 mg for the fetus/placenta, 500 mg for maternal red cell mass expansion, and 200 mg for obligatory losses). While a balanced diet provides roughly 10–15 mg of iron daily, only about 10% (1–1.5 mg) is absorbed. Even with the physiological increase in absorption during the second and third trimesters, dietary intake alone cannot meet the heightened demand of 4–6 mg/day required in later pregnancy. Therefore, routine **prophylactic oral iron supplementation** (60 mg elemental iron) is mandatory to prevent iron deficiency anemia. **Analysis of Incorrect Options:** * **B. Protein:** Requirements increase by about 25g/day (total ~75-80g). This can be easily achieved through protein-rich foods like pulses, eggs, milk, and lean meats. * **C. Carbohydrate:** The primary energy source. While the caloric demand increases by ~350 kcal/day in the 2nd and 3rd trimesters, this is easily met by increasing the portion size of staples (cereals/grains). * **D. Fats:** Essential for fetal brain development and fat-soluble vitamin absorption. Dietary fats (visible and invisible) are typically sufficient in a standard maternal diet. **NEET-PG High-Yield Pearls:** * **Iron absorption:** Enhanced by Vitamin C (Ascorbic acid) and inhibited by phytates, phosphates, and tea/coffee. * **Folic Acid:** While also supplemented to prevent Neural Tube Defects (NTDs), the question specifically highlights iron as the nutrient most difficult to recoup via diet alone due to poor bioavailability. * **WHO/IFA Guidelines:** Under the *Anemia Mukt Bharat* strategy, pregnant women should receive 60 mg elemental iron + 500 mcg folic acid daily for 180 days, starting from the second trimester.

Question 156: What is the daily requirement of calcium during pregnancy, in mg?

A. 600
B. 800
C. 1000
D. 1200 (Correct Answer)

Explanation: **Explanation:** The correct answer is **1200 mg/day**. During pregnancy, there is a significant physiological demand for calcium to support fetal skeletal development, particularly during the third trimester when bone mineralization peaks. To meet these demands without depleting maternal bone mineral density, the **Indian Council of Medical Research (ICMR)** and the **World Health Organization (WHO)** recommend an intake of **1200 mg/day** for pregnant and lactating women. * **Option A (600 mg):** This is the RDA for a non-pregnant, non-lactating adult woman. It is insufficient to meet the dual needs of the mother and the growing fetus. * **Option B (800 mg):** While some international guidelines (like the US RDA) suggest 1000 mg, 800 mg remains sub-optimal according to Indian standards (ICMR), which account for lower baseline dietary calcium intake in the population. * **Option C (1000 mg):** This is the standard recommendation for pregnant women in many Western countries; however, for NEET-PG, we follow the ICMR/NICE guidelines which specify 1200 mg. **High-Yield Clinical Pearls for NEET-PG:** * **Preeclampsia Prevention:** Calcium supplementation (1.5–2.0 g/day) is proven to reduce the risk of preeclampsia, especially in populations with low dietary calcium intake. * **Absorption:** Calcium should not be taken simultaneously with Iron supplements, as they inhibit each other's absorption. A gap of at least 3–4 hours is recommended. * **Fetal Transfer:** Approximately 25–30g of calcium is transferred to the fetus by term, 80% of which occurs in the third trimester.

Question 157: What is the earliest sign of pregnancy-induced hypertension?

A. Rapid gain in weight
B. High blood pressure (Correct Answer)
C. Albuminuria
D. Edema

Explanation: **Explanation:** The diagnosis of Pregnancy-Induced Hypertension (PIH) or Preeclampsia is clinically defined by the new onset of hypertension (BP ≥140/90 mmHg) after 20 weeks of gestation. **High blood pressure** is considered the earliest and most reliable sign because it is the primary diagnostic criterion. While physiological changes occur earlier at the molecular level (vasospasm and endothelial dysfunction), hypertension is the first clinical manifestation that alerts a clinician to the condition. **Analysis of Incorrect Options:** * **Rapid gain in weight:** While often the first *warning sign* (due to occult edema/fluid retention), it is non-specific. Many healthy pregnancies involve weight gain, and it is no longer a formal diagnostic criterion for PIH. * **Edema:** Pathological edema (swelling of the face, hands, or abdominal wall) was previously part of the diagnostic triad but has been removed because it occurs in up to 80% of normal pregnancies. It is a common symptom but not the earliest diagnostic sign. * **Albuminuria (Proteinuria):** This is usually a later manifestation indicating glomerular damage (endotheliosis). In modern guidelines, preeclampsia can be diagnosed even in the absence of proteinuria if other signs of end-organ damage are present. **NEET-PG High-Yield Pearls:** * **Definition:** BP ≥140/90 mmHg on two occasions, at least 4 hours apart, after 20 weeks in a previously normotensive woman. * **Roll-over Test:** Used as a predictive test for PIH between 28–32 weeks; a rise in diastolic BP >20 mmHg when turning from lateral to supine is positive. * **Drug of Choice:** Labetalol is the first-line antihypertensive; Magnesium Sulfate ($MgSO_4$) is the drug of choice for seizure prophylaxis (Eclampsia).

Question 158: A 28-year-old primigravida has a pre-pregnancy BMI of 30 kg/m². What is the recommended weight gain for her during pregnancy?

A. 5-7 kg (Correct Answer)
B. 8-11 kg
C. 10-13 kg
D. 14-16 kg

Explanation: ### Explanation The recommended weight gain during pregnancy is strictly determined by the patient’s **pre-pregnancy Body Mass Index (BMI)**. This guideline ensures optimal fetal growth while minimizing maternal complications like gestational diabetes, pre-eclampsia, and macrosomia. **1. Why Option A is Correct:** The patient is a primigravida with a BMI of **30 kg/m²**, which classifies her as **Obese** (BMI ≥ 30). According to the Institute of Medicine (IOM) and ACOG guidelines: * **Obese (BMI ≥ 30):** Recommended weight gain is **5–9 kg** (often simplified to 5–7 kg in Indian clinical contexts and exams). * The goal for obese women is to limit gain to the minimum required for fetal and placental development to avoid postpartum weight retention and metabolic risks. **2. Why Other Options are Incorrect:** * **Option B (8–11 kg):** This is the recommendation for **Overweight** women (BMI 25–29.9 kg/m²), where the range is 7–11.5 kg. * **Option C (10–13 kg):** This is the standard recommendation for women with a **Normal BMI** (18.5–24.9 kg/m²), where the range is 11.5–16 kg. * **Option D (14–16 kg):** This is recommended for **Underweight** women (BMI < 18.5 kg/m²), who require a higher gain of 12.5–18 kg to ensure adequate birth weight. **3. High-Yield Clinical Pearls for NEET-PG:** * **Twin Pregnancy:** Recommended gain is 17–25 kg for normal BMI, 14–23 kg for overweight, and 11–19 kg for obese. * **Rate of Gain:** In the 2nd and 3rd trimesters, a woman with a normal BMI should gain roughly **0.45 kg/week**, while an obese woman should gain only **0.22 kg/week**. * **Weight Loss:** Intentional weight loss during pregnancy is **never** recommended, even for morbidly obese patients.

Question 159: All of the following interventions are recommended to prevent mother-to-child transmission of HIV, except?

A. Avoid breast feeding
B. Highly Active Antiretroviral Therapy (HAART)
C. Vaginal delivery (Correct Answer)
D. Intrapartum Zidovudine

Explanation: **Explanation:** The primary goal of managing HIV in pregnancy is to reduce the **Mother-to-Child Transmission (MTCT)** rate from approximately 25–40% (without intervention) to less than 1–2%. **Why "Vaginal Delivery" is the correct answer (the exception):** Vaginal delivery is generally avoided in HIV-positive women if the viral load is high or unknown, as it exposes the neonate to infected maternal blood and cervicovaginal secretions. **Elective Cesarean Section (at 38 weeks)** is the preferred mode of delivery to minimize this risk, especially if the viral load is **>1000 copies/mL**. *Note: Vaginal delivery is only considered an option if the viral load is consistently <50 copies/mL near term.* **Analysis of Incorrect Options:** * **Highly Active Antiretroviral Therapy (HAART):** This is the cornerstone of prevention. It reduces maternal viral load, thereby decreasing the risk of transplacental and intrapartum transmission. * **Avoid Breastfeeding:** Postnatal transmission through breast milk accounts for a significant percentage of infections. In resource-rich settings and for exams like NEET-PG, **exclusive replacement feeding** is recommended to eliminate this risk. * **Intrapartum Zidovudine:** Intravenous Zidovudine (AZT) administered during labor/delivery further reduces the risk of transmission, particularly in women with suboptimal viral suppression. **High-Yield Clinical Pearls for NEET-PG:** * **Best predictor of transmission:** Maternal plasma viral load. * **Zidovudine prophylaxis for the neonate:** Should be started within 6–12 hours of birth and continued for 6 weeks. * **Avoid:** Artificial rupture of membranes (ARM), fetal scalp electrodes, and instrumental delivery (forceps/vaccum), as these increase the risk of micro-transfusions. * **WHO/NACO Guidelines:** In India, the current protocol emphasizes "Option B+": initiating lifelong ART for all pregnant and breastfeeding women living with HIV, regardless of CD4 count.

Question 160: Gestational sac can be seen earliest on transvaginal scan at what gestational age?

A. 4-5 weeks (Correct Answer)
B. 5-6 weeks
C. 7-8 weeks
D. 10 weeks

Explanation: **Explanation:** The visualization of pregnancy milestones via ultrasound is a high-yield topic for NEET-PG. The correct answer is **4-5 weeks** because the gestational sac (GS) is the first sonographic evidence of pregnancy. **1. Why 4-5 weeks is correct:** Using a high-frequency **Transvaginal Scan (TVS)**, the gestational sac can be visualized as early as **4 weeks + 3 days**. At this stage, it appears as a small, eccentric fluid collection (the "intradecidual sign") within the thickened endometrium. By 5 weeks, the sac is clearly visible with a mean sac diameter (MSD) of approximately 2–5 mm. **2. Analysis of Incorrect Options:** * **5-6 weeks:** While the **Yolk Sac** appears at 5 weeks and the **Fetal Pole (with cardiac activity)** appears at 5.5 to 6 weeks via TVS, the gestational sac itself is visible much earlier. * **7-8 weeks:** This is the timeframe when structures are easily seen via **Transabdominal Scan (TAS)**. TAS lags behind TVS by about 1 week in sensitivity. * **10 weeks:** By this stage, the embryo has developed into a fetus with recognizable limbs and organogenesis is well underway. **3. Clinical Pearls for NEET-PG:** * **Discriminatory Zone:** This is the serum β-hCG level at which a gestational sac should definitely be seen. For TVS, it is **1,500–2,000 mIU/mL**; for TAS, it is **3,000–3,500 mIU/mL**. * **Rule of 4-5-6 (TVS):** * 4.5 weeks: Gestational Sac * 5.5 weeks: Yolk Sac (confirms intrauterine pregnancy) * 6.5 weeks: Fetal Pole with Heartbeat * **Double Decidual Sac Sign:** A classic USG feature of an early IUP, helping to differentiate it from a pseudogestational sac seen in ectopic pregnancies.

Practice by Chapter

Preconception Counseling

Practice Questions

Pregnancy Diagnosis and Dating

Practice Questions

Routine Antenatal Assessments

Practice Questions

Maternal Physiological Changes

Practice Questions

Nutrition in Pregnancy

Practice Questions

Screening Tests in Pregnancy

Practice Questions

Fetal Growth Assessment

Practice Questions

High-Risk Pregnancy Identification

Practice Questions

Antenatal Complications Management

Practice Questions

Psychosocial Aspects of Pregnancy

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free